Volume Alert - TEVA 57.70 Teva Pharmaceutical Industries Ltd $TEVA Hit a high today of 58.17 Closing the day 11/07/14 at 57.70 -1.02 -1.74% With a day low of 56.95 and a total volume of 6,540,523.
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 320.75 (-2.72), ALNY: 95.84 (+2.93), ISIS: 44.59 (-0.66), OGXI: 2.18 (-0.02), TEVA: 57.70 (-1.02), RGLS: 22.08 (+2.42), GSK: 44.91 (+0.16), SNY: 45.69 (-0.17)
Uptrend Call Working As Teva Pharmaceutical Industries Stock Rises 10.2% (TEVA)
Comtex SmarTrend(R) - Fri Nov 07, 10:06AM CST
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on October 21st, 2014 at $52.51. In approximately 2 weeks, Teva Pharmaceutical Industries has returned 10.17% as of today's recent price of $57.85.
TEVA: 57.70 (-1.02)
Teva Presents Positive Safety and Efficacy Data for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL(R) (beclomethasone dipropionate) Nasal Aerosol 80 g/day in children 4-11 years of age with perennial - or "year round" - allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older. The data will be presented at the 2014 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Atlanta, Georgia on Saturday, November 8 and Sunday, November 9.
TEVA: 57.70 (-1.02)
Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia on November 6-10, 2014.
TEVA: 57.70 (-1.02)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 198.58 (-1.37), PFE: 29.92 (-0.12), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), TEVA: 57.70 (-1.02), ITCI: 15.26 (-0.21), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), OMER: 17.37 (+0.09)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.16 (+0.18), FURX: 104.77 (-1.41), SYN: 1.49 (+0.07), IRWD: 13.84 (+0.42), LXRX: 1.35 (-0.13), AZN: 72.88 (+0.03), TEVA: 57.70 (-1.02)
Global Nerve Gas & Pestiside Poisioning Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ccdnh/nerve_gas_and) has announced the addition of the "Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Teva Pharmaceutical Industries Limited - PharmAthene, Inc. - Protalix BioTherapeutics, Inc. - PlantForm Corporation Drug Profiles - atropine sulfate - PRX-105 - Plasma Derived Butyrylcholinesterase - Second Generation Protexia - Peptides for Nerve Gas and Pestiside Poisioning - Recombinant Butyrylcholinesterase For more information visit http://www.researchandmarkets.com/research/9c...ve_gas_and
BAX: 70.61 (-0.99), PIP: 1.72 (-0.01), TEVA: 57.70 (-1.02)
After Yesterday's Rally of 1.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 3:57PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.78 to a high of $58.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $58.25 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.70 (-1.02)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 57.70 (-1.02), LLY: 66.60 (-0.36), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.32 (-0.03), PFE: 29.92 (-0.12), AZN: 72.88 (+0.03), TTHI: 6.43 (-0.01), TEVA: 57.70 (-1.02), ITCI: 15.26 (-0.21), LLY: 66.60 (-0.36), OMER: 17.37 (+0.09)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 70.61 (-0.99), TEVA: 57.70 (-1.02), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNTA: 10.98 (+0.10), NVS: 91.76 (-0.27)
Global Intrauterine Contraceptive Devices Market Research Report 2014
M2 - Wed Nov 05, 11:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2jb3t/micro_market) has announced the addition of the "Micro Market Monitor: Global Intrauterine Contraceptive Devices Market Research Report" report to their offering. Intrauterine Contraceptive Devices and its peer markets - Ear, Nose & Throat Devices, Mobility Aid Devices , Feeding Device(Nutrition), Diagnostic Imaging, Nephrology/Urology Devices, Dermatology Devices, Cardiology Devices, Point of Care Testing, General & Plastic Surgery and 20 other markets - adds up to total Medical Devices market. Intrauterine Contraceptive Devices can be segmented by Technologies and Usages. Technologies of this market are Copper IUD, Hormone-releasing IUD and Inert IUD. Usages of this market are Short Term, Mid Term and Long Term. Audience for this report - Global Intrauterine Contraceptive Devices companies - Manufacturing Companies - Traders, distributors, and suppliers - Governmental and research organizations - Associations and industry bodies - Technology providers Key Topics Covered: 1 Executive Summary 2 Market Overview 3 Market Dynamics 4 Intrauterine Contraceptive Devices (Iucd) Market, By Type 5 Competitive Landscape 6 Company Profiles - Actavis Plc - Bayer Healthcare Ag (A Subsidiary Of Bayer Ag) - Medicines360 - Medisafe Distribution Inc. - Teva Pharmaceutical Industries Ltd. - Trimedic Supply Network Ltd. For more information visit http://www.researchandmarkets.com/research/n2...cro_market
TEVA: 57.70 (-1.02)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 91.06 (-3.49), ACT: 245.91 (-4.47), MYL: 53.11 (-0.39), TEVA: 57.70 (-1.02)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), TEVA: 57.70 (-1.02)
Key Takeaways From Teva Pharmaceutical Industries Ltd.'s Third-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Tue Nov 04, 5:35PM CST
Pharma companies far and wide are going through a difficult period because of the patent cliff. On the flip side, specialty and generic drugmakers have largely been the beneficiaries of top-selling drugs losing exclusivity, driving nice upticks in...
TEVA: 57.70 (-1.02)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 196.00 (-1.40), ABBV: 61.50 (-1.21), TEVA: 57.70 (-1.02), BMY: 58.32 (-0.14)
Quarterly Earnings Releases, Strategic Partnerships, and Scheduled Financial Results - Research Reports on Banco Bradesco, Blackstone, Teva, Apache and Noble
PR Newswire - Tue Nov 04, 7:45AM CST
Today, Analysts Review released its research reports regarding Banco Bradesco S.A. (NYSE: BBD), The Blackstone Group L.P. (NYSE: BX), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Apache Corp. (NYSE: APA) and Noble Corp. Plc (NYSE: NE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7667-100free.
BX: 31.14 (+0.84), BBD: 14.10 (+0.08), APA: 76.52 (+1.08), TEVA: 57.70 (-1.02), NE: 21.83 (+0.71)
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Business Wire - Tue Nov 04, 7:02AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS). Additionally, Teva has screened the first patient in the LEGATO-HD trial, which will evaluate laquinimod in Huntington's disease. Currently, there are no approved therapies available for the treatment of PPMS or the treatment of Huntington's disease, beyond symptom management.
TEVA: 57.70 (-1.02)
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 320.75 (-2.72), ALNY: 95.84 (+2.93), ISIS: 44.59 (-0.66), OGXI: 2.18 (-0.02), TEVA: 57.70 (-1.02), RGLS: 22.08 (+2.42), GSK: 44.91 (+0.16), SNY: 45.69 (-0.17)
Uptrend Call Working As Teva Pharmaceutical Industries Stock Rises 10.2% (TEVA)
Comtex SmarTrend(R) - Fri Nov 07, 10:06AM CST
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on October 21st, 2014 at $52.51. In approximately 2 weeks, Teva Pharmaceutical Industries has returned 10.17% as of today's recent price of $57.85.
TEVA: 57.70 (-1.02)
Teva Presents Positive Safety and Efficacy Data for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL(R) (beclomethasone dipropionate) Nasal Aerosol 80 g/day in children 4-11 years of age with perennial - or "year round" - allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older. The data will be presented at the 2014 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Atlanta, Georgia on Saturday, November 8 and Sunday, November 9.
TEVA: 57.70 (-1.02)
Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia on November 6-10, 2014.
TEVA: 57.70 (-1.02)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 198.58 (-1.37), PFE: 29.92 (-0.12), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), TEVA: 57.70 (-1.02), ITCI: 15.26 (-0.21), ABBV: 61.50 (-1.21), BMY: 58.32 (-0.14), OMER: 17.37 (+0.09)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.16 (+0.18), FURX: 104.77 (-1.41), SYN: 1.49 (+0.07), IRWD: 13.84 (+0.42), LXRX: 1.35 (-0.13), AZN: 72.88 (+0.03), TEVA: 57.70 (-1.02)
Global Nerve Gas & Pestiside Poisioning Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ccdnh/nerve_gas_and) has announced the addition of the "Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Teva Pharmaceutical Industries Limited - PharmAthene, Inc. - Protalix BioTherapeutics, Inc. - PlantForm Corporation Drug Profiles - atropine sulfate - PRX-105 - Plasma Derived Butyrylcholinesterase - Second Generation Protexia - Peptides for Nerve Gas and Pestiside Poisioning - Recombinant Butyrylcholinesterase For more information visit http://www.researchandmarkets.com/research/9c...ve_gas_and
BAX: 70.61 (-0.99), PIP: 1.72 (-0.01), TEVA: 57.70 (-1.02)
After Yesterday's Rally of 1.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 3:57PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.78 to a high of $58.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $58.25 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.70 (-1.02)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 57.70 (-1.02), LLY: 66.60 (-0.36), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16), BMY: 58.32 (-0.14)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.32 (-0.03), PFE: 29.92 (-0.12), AZN: 72.88 (+0.03), TTHI: 6.43 (-0.01), TEVA: 57.70 (-1.02), ITCI: 15.26 (-0.21), LLY: 66.60 (-0.36), OMER: 17.37 (+0.09)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 70.61 (-0.99), TEVA: 57.70 (-1.02), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNTA: 10.98 (+0.10), NVS: 91.76 (-0.27)
Global Intrauterine Contraceptive Devices Market Research Report 2014
M2 - Wed Nov 05, 11:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2jb3t/micro_market) has announced the addition of the "Micro Market Monitor: Global Intrauterine Contraceptive Devices Market Research Report" report to their offering. Intrauterine Contraceptive Devices and its peer markets - Ear, Nose & Throat Devices, Mobility Aid Devices , Feeding Device(Nutrition), Diagnostic Imaging, Nephrology/Urology Devices, Dermatology Devices, Cardiology Devices, Point of Care Testing, General & Plastic Surgery and 20 other markets - adds up to total Medical Devices market. Intrauterine Contraceptive Devices can be segmented by Technologies and Usages. Technologies of this market are Copper IUD, Hormone-releasing IUD and Inert IUD. Usages of this market are Short Term, Mid Term and Long Term. Audience for this report - Global Intrauterine Contraceptive Devices companies - Manufacturing Companies - Traders, distributors, and suppliers - Governmental and research organizations - Associations and industry bodies - Technology providers Key Topics Covered: 1 Executive Summary 2 Market Overview 3 Market Dynamics 4 Intrauterine Contraceptive Devices (Iucd) Market, By Type 5 Competitive Landscape 6 Company Profiles - Actavis Plc - Bayer Healthcare Ag (A Subsidiary Of Bayer Ag) - Medicines360 - Medisafe Distribution Inc. - Teva Pharmaceutical Industries Ltd. - Trimedic Supply Network Ltd. For more information visit http://www.researchandmarkets.com/research/n2...cro_market
TEVA: 57.70 (-1.02)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 91.06 (-3.49), ACT: 245.91 (-4.47), MYL: 53.11 (-0.39), TEVA: 57.70 (-1.02)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 196.00 (-1.40), ACT: 245.91 (-4.47), TEVA: 57.70 (-1.02)
Key Takeaways From Teva Pharmaceutical Industries Ltd.'s Third-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Tue Nov 04, 5:35PM CST
Pharma companies far and wide are going through a difficult period because of the patent cliff. On the flip side, specialty and generic drugmakers have largely been the beneficiaries of top-selling drugs losing exclusivity, driving nice upticks in...
TEVA: 57.70 (-1.02)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 196.00 (-1.40), ABBV: 61.50 (-1.21), TEVA: 57.70 (-1.02), BMY: 58.32 (-0.14)
Quarterly Earnings Releases, Strategic Partnerships, and Scheduled Financial Results - Research Reports on Banco Bradesco, Blackstone, Teva, Apache and Noble
PR Newswire - Tue Nov 04, 7:45AM CST
Today, Analysts Review released its research reports regarding Banco Bradesco S.A. (NYSE: BBD), The Blackstone Group L.P. (NYSE: BX), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Apache Corp. (NYSE: APA) and Noble Corp. Plc (NYSE: NE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7667-100free.
BX: 31.14 (+0.84), BBD: 14.10 (+0.08), APA: 76.52 (+1.08), TEVA: 57.70 (-1.02), NE: 21.83 (+0.71)
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Business Wire - Tue Nov 04, 7:02AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS). Additionally, Teva has screened the first patient in the LEGATO-HD trial, which will evaluate laquinimod in Huntington's disease. Currently, there are no approved therapies available for the treatment of PPMS or the treatment of Huntington's disease, beyond symptom management.
TEVA: 57.70 (-1.02)
